Enhancing drug synergy in malignant diseases with deep architecture optimization algorithms

Read full text Summarise with VIRAT
Authors: Pooja Rani, Kamlesh Dutta, Vijay Kumar
Cited by: 0
References: 89

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Malignant diseases remain one of the leading causes of death globally. Drug synergy has emerged as an effective approach for treating malignancy, offering improved therapeutic outcomes. Although techniques like clinical trials and high-throughput drug screening are commonly used to discover promising synergistic drug pairs, but they are time consuming and expensive. With the evolution of artificial intelligence, deep learning models are increasingly being applied to identify synergistic drug combinations. These models rely heavily on large-scale datasets, where size of dataset and hyperparameter selection play a pivotal role in the performance of model. However, determining the optimal hyperparameters for drug synergy models is a complex and time-intensive task, typically involving multiple iterative experiments. As a result, there is growing attention on optimizing hyperparameters for these models. This study emphasizes the role of hyperparameter optimization algorithms (HOAs) in evaluating how different optimization strategies and hyperparameter choices influence model effectiveness. By optimizing the hyperparameters, we achieved good accuracy in predicting drug synergy. Our findings highlight that the effectiveness of hyperparameter optimization is highly task- and dataset-dependent.

Fields of Study & Subjects

Computational Drug Discovery Methods Machine Learning and Data Classification Machine Learning in Materials Science

Publication details

Journal / source
Computer Methods in Biomechanics & Biomedical Engineering
Pages
1–18
Publication date
26 March 2026
Language
EN